Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Acalabrutinib in #Waldenström macroglobulinemia -> durable responses w/ 5 year follow-up; ORR 92.9% and 94.6% in TN and R/R cohorts; median PFS NE and 67.5 mos, DOR NR and 64.7 mos, OS NR in both (66-month OS rate 90.9% and 71.2%).”
Title: Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up
Authors: Roger G Owen, Helen McCarthy, Shirley D’Sa, Sheeba K Thomas, Olivier Tournilhac, Francesco Forconi, Marie José Kersten, Pier Luigi Zinzani, Sunil Iyengar, Jaimal Kothari, Monique C Minnema, Efstathios Kastritis, Bruce David Cheson, Harriet Sarah Walter, Daniel Greenwald, Roser Calvo, Yi Li, Simon Rule, Richard R Furman
You can read the Full Article in Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
